Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Pfizer
(NY:
PFE
)
28.84
-0.09 (-0.30%)
Streaming Delayed Price
Updated: 12:48 PM EDT, Sep 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Pfizer
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
10 Best Ultra-High-Yield Dividend Stocks to Consider as Part of a Long-Term Portfolio
July 30, 2024
These ultra-high-yield dividend stocks could be a great fit for a long-term-oriented portfolio.
Via
The Motley Fool
Is Bristol Myers Squibb a Good Dividend Stock to Buy Now?
July 30, 2024
A lowered outlook for 2024 and upcoming patent expirations have investors concerned about this pharmaceutical giant's dividend program.
Via
The Motley Fool
Topics
Intellectual Property
Exposures
Intellectual Property
US Stocks Close Mixed Ahead Of Big Earnings, Fed Decision: Investor Optimism Improves Further
July 30, 2024
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Procter & Gamble, Microsoft And 3 Stocks To Watch Heading Into Tuesday
July 30, 2024
Via
Benzinga
Pfizer Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
July 30, 2024
Via
Benzinga
(PFE) - Analyzing Pfizer's Short Interest
July 29, 2024
Via
Benzinga
Apple, Amazon, Microsoft, Meta Lead The Charge As Investors Bank On Tech Cheer For Rally's Reacceleration: Week Ahead In Earnings
July 29, 2024
The unfolding week's market trajectory depends on earnings from bellwether tech stocks and what the Fed has to say following its July meeting.
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Pfizer's Options: A Look at What the Big Money is Thinking
July 25, 2024
Via
Benzinga
Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 3% Dividend Yields
July 29, 2024
Via
Benzinga
How To Earn $500 A Month From Pfizer Stock Ahead Of Q2 Earnings
July 29, 2024
Pfizer Inc (PFE) expected to release Q2 financial results on Tuesday before opening bell. Analysts predict earnings at 46 cents/share, down from 67 cents last year. Stock gained 3.4% to close at $30.77...
Via
Benzinga
Prediction: This Will Be Pfizer's Next Big Move
July 29, 2024
One market in particular is too lucrative for it to miss out on any longer.
Via
The Motley Fool
3 Ultra-High-Yield Dividend Stocks to Buy Now and Hold Forever
July 29, 2024
Any of these three stocks could be the backbone of a solid dividend portfolio.
Via
The Motley Fool
2 Incredibly Cheap Healthcare Stocks to Buy Now
July 28, 2024
Sometimes a beaten-down stock can present a valuable opportunity.
Via
The Motley Fool
2 High-Yield Dividend Stocks That Could Shine in 2025
July 27, 2024
With interest rates expected to decline, high-yield dividend stocks offer attractive income potential and possible capital appreciation.
Via
The Motley Fool
2 Unstoppable Growth Stocks to Buy Right Now for Less Than $200
July 27, 2024
These stocks are trading on sale, but a closer look from investors is warranted.
Via
The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
July 26, 2024
Via
Benzinga
3 Surprisingly Underrated Stocks to Buy Right Now
July 26, 2024
These stocks arguably deserve more respect from investors.
Via
The Motley Fool
Freeport-McMoRan, Pfizer, Danaher And An Industrial Stock: CNBC's 'Final Trades'
July 26, 2024
Freeport-McMoRan is Bryn Talkington's "final trade." On July 23, Freeport-McMoRan said second-quarter revenue came in at $6.62 billion.
Via
Benzinga
Get Your Money Out of These 3 Dividend Stocks by 2025
July 26, 2024
Discover the three dividend stocks you should sell by 2025 for better returns. Get insights into why these 3 stocks could disappoint you.
Via
InvestorPlace
What's Going On With Pfizer Stock Thursday?
July 25, 2024
Pfizer is anticipated to report quarterly financial earnings on Tuesday before the market opens. In addition, the European Commission approved Pfizer's DURVEQTIX.
Via
Benzinga
7 Dividend Stocks to Hold On Tight to for the Next Decade
July 25, 2024
Discover the top long-term dividend stocks across pharmaceuticals, asset management, REITs, telecommunications, and tobacco.
Via
InvestorPlace
3 Stocks That Can Help You to Get Richer in 2024 and Beyond
July 25, 2024
Good bargains still abound in the market, and two of the stocks below offer fat dividends as well.
Via
The Motley Fool
Beware, Wegovy -- Pfizer Is Working on a Competitor
July 25, 2024
Pfizer wants to maintain its recent run of key approvals.
Via
The Motley Fool
Why Is Sangamo Therapeutics (SGMO) Stock Up 40% Today?
July 24, 2024
Little-known firm Sangamo Therapeutics is surging today, with SGMO stock up more than 40% on promising late-stage trial results.
Via
InvestorPlace
Sangamo Stock Spikes As Pfizer Partnership Meets Goal In Late-Stage Study
July 24, 2024
Pfizer's Phase 3 AFFINE study of giroctocogene fitelparvovec gene therapy for hemophilia A meets key endpoints, showing a significant reduction in annualized bleeding rate.
Via
Benzinga
This Promising Weight Loss Drug Candidate Could Be a Huge Growth Catalyst for Pfizer
July 24, 2024
With danuglipron, Pfizer could become a major player in the massive GLP-1 agonist market.
Via
The Motley Fool
Novo Nordisk's Stock Dips In Pre-Market Despite Winning UK's Approval Of Weight Loss Drug: What's Going On
July 24, 2024
Wegovy, a GLP-1 receptor agonist, had previously been approved for use in obesity treatment and weight management.
Via
Benzinga
Merck Competes With Sanofi/AstraZeneca As Its RSV Treatment Drug Meets Primary Goal In Late-Stage Study In Infants
July 23, 2024
Merck shares topline results from its Phase 2b/3 trial of clesrovimab, showing efficacy in reducing RSV-related infections in infants. Clesrovimab met safety and efficacy endpoints.
Via
Benzinga
Pfizer And GSK's ViiV Healthcare's Two-Drug HIV Treatment Matches Gilead's Three-Drug Combo In Major Trial
July 23, 2024
ViiV Healthcare's Dovato matches Gilead's Biktarvy in effectiveness for HIV treatment. The study reveals Dovato's benefit of less weight gain compared to Biktarvy, highlighting its efficacy and patient...
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
July 23, 2024
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.